MedTrace Logo

ACCURATE Study for Subjects With Dry Eyes

NCT04237012 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-11-29

No results posted yet for this study

Summary

To determine treatment and imaging outcomes in bilateral ocular surface disease management with an intracanalicular dexamethasone (0.4 mg) insert compared to standard topical over-the-counter artificial tears lubrication management

Conditions

  • Dry Eye Syndromes

Interventions

DRUG

Dextenza 0.4Mg Intracanalicular Insert

all patients will receive Intracanalicular dexamethasone, 0.4mg insert lower punctum and able to use over the counter artificial tears PRN at patient discretion

OTHER

Over the counter Artificial tears

over the counter artificial tears PRN at patient discretion

Sponsors & Collaborators

  • The Eye Centers of Racine and Kenosha

    lead OTHER

Principal Investigators

  • Inder P Singh, M.D. · President

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-16
Primary Completion
2021-12-30
Completion
2021-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04237012 on ClinicalTrials.gov